Drugs / Adipose tissue derived mesenchymal stem cell
Adipose tissue derived mesenchymal stem cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02966951 | Jan 2017 → Sep 2021 | osteoarthritis, knee | Hanan Jafar | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose tissue derived mesenchymal stem cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02966951 ↗ |
| Known as | ADMSCs | “This study evaluates the safety and efficacy of allogeneic adipose-derived mesenchymal stromal cells (ADMSCs) injected under ultrasound guidance” PMID 42049633 ↗ Apr 2026 |
| Known as | allogeneic adipose-derived mesenchymal stromal cells | “This study evaluates the safety and efficacy of allogeneic adipose-derived mesenchymal stromal cells (ADMSCs) injected under ultrasound guidance” PMID 42049633 ↗ Apr 2026 |
| Known as | ATMSC | “Adipose tissue derived Mesenchymal Stem cells (ATMSC) will be injected in patients diagnosed with Knee osteoarthrosis” NCT02966951 ↗ |
| Modality | Cell therapy | “This study evaluates the safety and efficacy of allogeneic adipose-derived mesenchymal stromal cells (ADMSCs) injected under ultrasound guidance” PMID 42049633 ↗ Apr 2026 |